Angiodynamics vs Inogen
Angiodynamics and Inogen are similar in size: $320m and $349m of revenue in their latest fiscal years. Angiodynamics grew faster (9.5% against 3.9%). Inogen kept more of each dollar of sales as profit: a net margin of -6.5% against -11.5%. Angiodynamics carries less debt relative to equity (0.0% against 0.0%).
| Latest fiscal year | AngiodynamicsANGO, 2026 | InogenINGN, 2025 |
|---|---|---|
| Revenue | $320m | $349m |
| Revenue growth | 9.5% | 3.9% |
| Net income | −$36.7m | −$22.7m |
| Operating margin | -12.5% | -8.7% |
| Net margin | -11.5% | -6.5% |
| Return on equity | -20.8% | -12.4% |
| Free cash flow | $508,000 | −$13.7m |
| Cash | $53.9m | $104m |
| Total debt | $0 | $0 |
| Debt to equity | 0.0% | 0.0% |
| Dividend per share | — | — |
| Dividend yield | — | — |
| Share buybacks | $0 | — |
| Employees | 632 | — |
| Market value | $499m | $184m |
| Price vs our value range | — | — |
| Moat score | 53 (Moderate) | 41 (Weak) |
| Insider trades, 12 months | 0 buys, 3 sales | 0 buys, 2 sales |